The board of directors biopharmaceutical company Merck (NYSE:MRK) declared a dividend of USD0.61 per share on the company's common stock for the second quarter of 2020, it disclosed on Tuesday.
This dividend is payable on 7 July 2020 to shareholders of record at the close of business as of 15 June 2020.
Merck said it continues to be at the forefront of research to prevent and treat diseases that threaten people and animals, including cancer, infectious diseases, HIV and Ebola, as well as emerging animal diseases.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients